tousled1
12-16-2007, 04:58 AM
A clinical trial of a new targeted breast cancer drug, led by physicians at Massachusetts General Hospital (MGH) Cancer Center, has begun enrolling patients. The TEACH (Tykerb Evaluation After CHemotherapy) trial will investigate the experimental drug Tykerb (lapatinib) in patients with early-stage, HER2-positive breast cancer who have not been treated with Herceptin, another targeted drug used for the same type of tumor. The MGH is the lead institution for the international trial, which is being sponsored by GlaxoSmithKline, the manufacturer of Tykerb.
Full article: http://www.sciencedaily.com/releases/2006/12/061213174625.htm
Full article: http://www.sciencedaily.com/releases/2006/12/061213174625.htm